Alprostadil (Caverject/MUSE) Cost in Delaware 2026

What Does Alprostadil Cost in Delaware in 2026?

The retail cash price for alprostadil in Delaware runs close to $600 per month for brand-name Caverject or MUSE in 2026. Generic alprostadil injection formulations are available and typically price lower, though exact figures vary by pharmacy. Patients using GoodRx or similar discount platforms at Delaware-based Walgreens, CVS, or Rite Aid locations may find prices between $180 and $450 per fill, depending on the dose and quantity dispensed.

Alprostadil works by relaxing smooth muscle in the corpus cavernosum, increasing arterial inflow and producing an erection suitable for intercourse. The drug's mechanism involves direct activation of adenylyl cyclase, raising cyclic AMP and causing vasodilation [1]. Because it acts locally rather than systemically, it remains an option for men who cannot tolerate phosphodiesterase-5 inhibitors such as sildenafil or tadalafil.

In the landmark Linet et al. trial published in the New England Journal of Medicine (N=683), intracavernosal alprostadil produced erections sufficient for intercourse in 94% of injection attempts versus 11% with placebo [2]. That efficacy record justifies its continued use even at higher price points. The FDA approved Caverject for erectile dysfunction in 1995 and MUSE (medicated urethral system for erection) in 1996 [3].

Price varies by dose. Caverject is supplied as lyophilized powder in 10 mcg and 20 mcg vials; MUSE suppositories come in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg strengths. Higher doses cost more per unit. A typical starting dose for intracavernosal injection is 2.5 mcg, titrated upward under physician supervision, which means a single box of 6 vials may last several weeks depending on frequency [4].

Delaware has no state-level price-control program specific to alprostadil, so patients pay whatever the pharmacy's contracted rate or cash price dictates. Comparing prices across at least three pharmacies before filling is a straightforward way to cut costs.

Does Delaware Medicaid Cover Alprostadil?

Delaware Medicaid covers alprostadil for refractory erectile dysfunction, but a prior authorization (PA) is required before the claim will process. The PA process asks the prescribing provider to document that the patient has failed or cannot tolerate oral PDE-5 inhibitors and that the ED has an organic cause [5].

Delaware's Medicaid program is administered through managed-care organizations (MCOs) that contract with the state. Each MCO maintains its own formulary, but erectile dysfunction drugs used for a documented medical indication generally qualify for coverage under Delaware Division of Medicaid and Medical Assistance (DMMA) rules. Providers should verify the specific MCO formulary before prescribing, because coverage tiers and PA criteria can differ slightly between plans.

When PA is approved, the beneficiary's cost-sharing is typically limited to the standard Medicaid copay, which in Delaware is $4 for most brand-name drugs and $1 for generics for most adult beneficiaries. That represents a dramatic reduction from the $600 cash price. Denials can be appealed; a letter from the treating urologist or primary-care physician detailing prior treatment failures usually strengthens an appeal [6].

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "For patients who do not respond to or cannot use PDE5Is, intracavernosal alprostadil is a second-line therapy with high efficacy rates and an acceptable side-effect profile" [7]. That language directly supports the medical-necessity argument used in PA requests.

Is Compounded Alprostadil Legal in Delaware?

Compounded alprostadil is legal in Delaware when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds on a patient-specific basis under a valid prescription from a licensed practitioner [8].

Delaware's State Board of Pharmacy licenses and inspects compounding pharmacies operating within the state. Out-of-state 503A pharmacies may also ship compounded alprostadil to Delaware patients provided they hold appropriate non-resident pharmacy permits and comply with Delaware law. The compound is typically formulated as a multi-drug injection (sometimes called "Trimix" when combined with papaverine and phentolamine, or "Bimix" without phentolamine), but single-agent compounded alprostadil is also available [9].

Cost for compounded alprostadil varies by pharmacy and formulation. Some telehealth platforms that work with 503A compounding pharmacies price it significantly below the $600 brand-name benchmark. Patients should confirm that any compounding pharmacy they use is licensed in Delaware and accredited by the Pharmacy Compounding Accreditation Board (PCAB) or a comparable body.

503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, are not the appropriate source for this compound because alprostadil for erectile dysfunction requires individualized dosing. The FDA distinguishes clearly between 503A and 503B operations and their legal dispensing pathways [8].

One clinical consideration: compounded formulations are not FDA-approved and have not gone through the same bioequivalence testing as Caverject. Efficacy data from trials such as Linet et al. apply to the FDA-approved product [2]. Prescribers and patients should weigh that distinction when choosing between branded and compounded options.

HealthRX Delaware Alprostadil Cost Decision Framework

Use this stepwise approach to find the lowest legal cost for alprostadil in Delaware:

1. Check Delaware Medicaid eligibility first. If enrolled, pursue PA documentation with your urologist or primary-care provider.
2. If privately insured, call the member-services number on your card and ask specifically whether alprostadil appears on the formulary under "erectile dysfunction, organic" and what PA criteria apply.
3. If uninsured or if insurance denies coverage, request Pfizer's co-pay assistance card (available at pfizer.com) and compare against GoodRx prices at three or more local Delaware pharmacies.
4. If the out-of-pocket cost still exceeds your budget after steps 1 through 3, ask your prescriber about a compounded formulation from a PCAB-accredited 503A pharmacy licensed in Delaware.
5. Document your cost comparisons in writing. If you later re-apply for Medicaid or appeal an insurance denial, that paper trail supports the financial-hardship component of the appeal.

How Delaware Insurance Plans Treat Alprostadil

Most commercial insurance plans available through Delaware's state exchange or employer groups cover alprostadil with prior authorization, though some plans exclude all erectile dysfunction drugs as a category. The Affordable Care Act does not mandate coverage of ED medications, so plan-to-plan variation is wide [10].

Checking coverage requires asking specifically about the drug's brand name (Caverject, MUSE) and its generic name (alprostadil) because formulary databases sometimes list them separately. Some formularies place the generic on Tier 2 (preferred brand) while the brand sits on Tier 3 or Tier 4. A Tier 3 co-pay in Delaware commercial plans often falls between $50 and $100 per fill, dropping the effective monthly cost well below the cash-pay rate [11].

Blue Cross Blue Shield of Delaware, Highmark, and Aetna are three major carriers offering plans in the Delaware market. Each publishes an online formulary search tool. Patients should search for "alprostadil" by generic name and note the tier, any quantity limits, and whether a PA is required. Quantity limits commonly cap coverage at six to twelve units per month.

For Medicare beneficiaries, Part D does not cover drugs "used for the treatment of sexual or erectile dysfunction unless such drug were used to treat a condition, other than sexual or erectile dysfunction, for which the drug has been approved by the FDA" [12]. That exclusion means most Medicare Part D plans will not cover Caverject or MUSE for ED, pushing Medicare patients toward the cash-pay or patient-assistance routes described below.

Telehealth Prescribing of Alprostadil in Delaware

Telehealth prescribing of alprostadil is legal in Delaware under current state telemedicine regulations. Delaware adopted rules permitting audio-video clinical encounters for prescription of controlled and non-controlled substances provided that the standard of care is met [13].

Alprostadil is not a controlled substance, which removes the stricter Ryan Haight Act requirements that apply to Schedule II through IV drugs. A licensed Delaware physician or advanced-practice provider conducting a telemedicine visit may therefore evaluate a patient's erectile dysfunction history, review prior treatment, and write an alprostadil prescription without a mandatory in-person visit, as long as the encounter meets the standard-of-care threshold for a valid prescriber-patient relationship [14].

Practical steps for a telehealth alprostadil visit in Delaware: the clinician will typically review the patient's cardiovascular history (important because vasodilatory drugs carry cardiac considerations), assess prior PDE-5 inhibitor use, and, if appropriate, issue a prescription that can be sent to the patient's local pharmacy or a licensed mail-order compounding pharmacy. The FDA-approved prescribing information for Caverject explicitly states that the first dose should be administered in a physician's office, with the patient observed for at least 30 minutes post-injection to monitor for prolonged erection (priapism) or hypotension [4]. Many telehealth providers satisfy this requirement by arranging an in-person first-dose visit with a local urologist or by scheduling a supervised first-use appointment.

The standard titration protocol for Caverject begins at 2.5 mcg for neurogenic ED and at 1.25 mcg for vasculogenic ED, with incremental increases of 2.5 to 5 mcg at the next visit until an adequate response is achieved with no more than a 1-hour erection [4]. Patients should be trained in proper injection technique before self-administering at home.

Discount Programs and Patient Assistance for Alprostadil in Delaware

Several cost-reduction pathways exist for Delaware patients paying out of pocket for alprostadil. Pfizer, the manufacturer of Caverject, runs a co-pay assistance program for commercially insured patients and a separate patient-assistance program (PAP) for uninsured or underinsured patients who meet income criteria. Applications are available through Pfizer's RxPathways program [15].

GoodRx coupons can reduce the cash price of generic alprostadil injection at major Delaware pharmacy chains. Prices using GoodRx at pharmacies in Wilmington, Dover, and Newark have ranged from approximately $180 to $380 per fill depending on dose and quantity, representing a savings of 30% to 70% below the list price. These coupons cannot be combined with insurance benefits but are freely available without a membership fee [16].

NeedyMeds and RxAssist maintain searchable databases of manufacturer patient-assistance programs. Delaware residents who earn less than 200% to 400% of the federal poverty level (depending on the program) may qualify for free or reduced-cost Caverject directly from Pfizer. The application process usually requires proof of income, a prescription, and a completed enrollment form signed by the prescribing physician [17].

Delaware's DMMA also administers the Delaware Prescription Assistance Program (DPAP), which helps low-income residents access medications not covered by other programs. DPAP eligibility is separate from Medicaid and covers residents who do not qualify for Medicaid but still face high drug costs [18].

State Health Insurance Assistance Program (SHIP) counselors in Delaware, funded through the Administration for Community Living, can help Medicare beneficiaries review their Part D options at no charge and may identify plans with the most favorable cost-sharing for alprostadil-related expenses, even where Part D excludes the drug directly.

Safety Profile and Why Cost Should Not Drive Dose Decisions

Alprostadil carries a well-characterized adverse-effect profile. Penile pain is the most commonly reported side effect, occurring in approximately 37% of patients in the Linet et al. trial [2]. Prolonged erection lasting more than 4 hours (priapism) is a medical emergency requiring immediate treatment; incidence in controlled trials was under 1% but rises with improper dosing [4]. Penile fibrosis has been reported with long-term use, particularly at higher doses or with improper injection technique [19].

These safety considerations matter in the context of cost because patients who ration their doses or use improperly stored compounded formulations to save money may inadvertently increase their risk. Expired or improperly reconstituted alprostadil may lose potency, prompting patients to use higher-than-prescribed doses, which elevates priapism risk. Caverject Impulse (the dual-chamber syringe formulation) is designed for single-use; reconstituted solution should not be stored for reuse [4].

The FDA's prescribing information states that alprostadil should not be used more than 3 times per week or more than once in any 24-hour period [4]. Those frequency limits are safety-based, not arbitrary, and they also define the ceiling on how much medication a patient actually needs per month, which in turn affects the cost calculation.

A 2021 systematic review in the Journal of Sexual Medicine (N=27 trials) confirmed that intracavernosal alprostadil produces clinically meaningful improvements in erectile function scores (International Index of Erectile Function domain 2, mean improvement +8.1 points versus baseline) across organic, psychogenic, and mixed-etiology ED [20].

Comparing Caverject, MUSE, and Compounded Options Side by Side

Caverject (intracavernosal injection) and MUSE (intraurethral suppository) are both FDA-approved alprostadil formulations but differ in delivery, efficacy, and price [3][4].

Caverject produces erections in roughly 70% to 80% of men in real-world use, a rate supported by multiple controlled trials. MUSE has a somewhat lower real-world efficacy, approximately 40% to 65%, because urethral absorption is less reliable than direct cavernosal injection [21]. MUSE may appeal to patients who are needle-averse, but its lower efficacy means some patients try it and then switch to Caverject.

On price, MUSE (available as Muse brand or generics) carries a list price similar to Caverject but may be found at slightly lower cash prices at certain Delaware pharmacies. Both are far more expensive than compounded intracavernosal formulations from 503A pharmacies.

Compounded Trimix (alprostadil plus papaverine plus phentolamine) is not an FDA-approved product, but published data support its use as a second-line intracavernosal therapy when single-agent alprostadil is insufficient or poorly tolerated. The 2018 AUA Erectile Dysfunction Guideline lists Trimix as an option for patients who do not respond to alprostadil monotherapy [7]. In Delaware, compounded Trimix from a licensed 503A pharmacy may cost $50 to $150 per vial, a substantial reduction from brand-name alprostadil pricing, though cost varies by pharmacy.

How to Get Alprostadil at the Lowest Legal Cost in Delaware: Step-by-Step

Getting alprostadil at the lowest price in Delaware is straightforward if approached methodically.

First, confirm your diagnosis of organic or mixed-etiology erectile dysfunction with a licensed provider. Delaware telehealth platforms can support this evaluation. Second, ask the provider to document prior PDE-5 inhibitor trials in the chart, because this documentation is required for nearly every PA process. Third, if you carry Medicaid, direct your provider to submit a PA to your specific MCO before the prescription is filled [5][6]. Fourth, if you carry commercial insurance, request a formulary exception if alprostadil is not covered or is on a high tier. Fifth, if uninsured, apply for Pfizer RxPathways assistance and compare GoodRx prices at three or more Delaware pharmacies before paying cash [15][16]. Sixth, if cost remains prohibitive after steps one through five, ask your provider to evaluate whether a compounded 503A formulation is clinically appropriate for your situation [8][9].

Patients in Wilmington can access urologists at Christiana Care Health System. Patients in Dover or Sussex County may work with providers at Bayhealth or Beebe Healthcare, both of which have telemedicine infrastructure. A telehealth provider licensed in Delaware can write the prescription and coordinate with any pharmacy in the state.

Delaware residents who qualify for DPAP should contact the program directly at (302) 255-9040 to confirm current eligibility thresholds and the list of covered drugs, since program parameters may update annually.